TABLE 1.
In vivo toxin neutralization and C57 protection by transferring BALB/c seraa
| Groups | Treatment | Mortality rate (dead/total) | Urea (median ± SEM; mg%) |
|---|---|---|---|
| BALB/c control | Stx2a i.v. | 5/5 | 326 ± 71 |
| BALB/c infected | Stx2a i.v. | 0/3b | 92 ± 26c |
| C57 infected | BALB/c control sera | 3/3 | 175 ± 21 |
| C57 infected | BALB/c infected sera | 0/3b | 106 ± 11c |
a
Control and infected BALB/c mice received 1 ng of Stx2a by intravenous (i.v) injection at day 7 p.i. C57 mice were i.p. injected with sera from noninfected (control) or infected BALB/c after infection, as detailed in the Materials and Methods. Mortality rate (dead/total) and plasma urea levels (mg%) at day 3 post Stx2a injection (for BALB/c experiments) or at day 3 p.i. (for C57 experiments) are shown.
b
Significantly different by log rank test (P < 0.05) compared with the respective control group.
c
Significantly different by Student's t test (P < 0.05) compared with the respective control group.